Download Citation
Article Source:
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
Troya J,
Ryan P,
Ribera E,
Podzamczer D,
Hontañón V,
et al.
(2017)
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
PLOS ONE 12(2): e0172184.
https://doi.org/10.1371/journal.pone.0172184